Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

ABSTRACT: BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

PROVIDER: PRJNA913003 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR22764212_1.fastq.gz	Fastqsanger.gz
	SRR22764212_2.fastq.gz	Fastqsanger.gz
	SRR22764213_1.fastq.gz	Fastqsanger.gz
	SRR22764213_2.fastq.gz	Fastqsanger.gz
	SRR22764214_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 16

Similar Datasets

Disruption of BMI1 dynamic balance blunts immunotherapy efficacy in HCC

Project description:Disruption of BMI1 dynamic balance blunts immunotherapy efficacy in HCC

| PRJNA911277 | ENA

Disruption of BMI1 dynamic balance blunts immunotherapy efficacy in HCC

Project description:To investigated how BMI1 inhibitor (PTC) affected the function of primary T cells, we treated Tcells with PTC. We then performed gene expression profiling analysis using data obtained from RNA-seq of peritoneal macrophages with PTC 209.

2024-05-29 | GSE220751 | GEO

BMI1 dynamic balance destroy blunts immunotherapy efficacy in HCC

Project description:m6A-binding RNAs were analyzed by imprinting RNA-sequencing of anti-m6A antibody-retrieved complexes from primary T cells. We then performed gene expression profiling analysis using data obtained from RIP-seq of primary T cells treated with PTC

2024-05-29 | GSE221120 | GEO

Disruption of BMI1 dynamic balance weakens immunotherapy efficacy in HCC

Project description:Low reactivity and short duration of tumor-infiltrated T cells limit HCC immunotherapy efficacy. The proliferative ability of T cells maybe accounts for these deficiencies. This study aimed to define the key factor regulating TILs proliferation in HCC microenvironment.

2023-01-14 | PXD039456 |

Targets of Bmi1 in HCC pathogenesis

Project description:Targets of Bmi1 in HCC pathogenesis

| PRJNA380877 | ENA

Gene expression in the Bmi1 knockout Huh7 and Hep3B cells

Project description:Bmi1 plays a pivotal role in hepatic carcinoma (HCC), but its targets in HCC is unknown. To screen the potential targets, we transfected HCC cell line Huh7 and Hep3B with Bmi1 shRNA lenti-virus. After confirming the Bmi1 was knocked down using western blotting, we extracted total RNA and then run the microarray detection. Gene expression profiles in Bmi1 KO cells were compared with those in Bmi1 WT cells to screen potential targets of Bmi1.

2018-03-29 | GSE97169 | GEO

Elucidation of BMI1, RYBP and H2AK119ub interactomes in Glioblastoma

Project description:Identification of BMI1, RYBP and H2AK119UB interactome in Glioblastoma (GBM) to elucidate BMI1 roles independent of the PRC1-complex in GBM.

2021-09-09 | PXD022057 | Pride

A cDNA microarray analysis was performed on shRNA KDs of EZH2, SUZ12, BMI1, or CBX8 HepG2 cells.

Project description:Polycomb group (PcG) proteins including EZH2, SUZ12 ,BMI1,CBX8 and so on, which specifically catalyze trimethylation of histone 3 lysine 27 (H3K27me3), and methylated H3K27 can be recognized by other specific binding proteins to compress chromatin structure, leading to the transcriptional repression of the target genes. To explore a potential functional implication of PcG components in HCC, we stably transfected HepG2 cells with either vectors or constructs expressing shRNA that specifically targets EZH2, SUZ12, BMI1, or CBX8. A cDNA microarray analysis was performed on shRNA KDs of EZH2, SUZ12, BMI1, or CBX8 HepG2 cells. To obtain a broader understanding of the molecular network of PcG in HCC, the whole genome microarray expression profiling was performed on shRNA KDs of EZH2, SUZ12, BMI1, or CBX8 HepG2 cells. Comparison of gene expression results from shRNA KDs of EZH2, SUZ12, BMI1 or CBX8 HepG2 cells.

2014-01-16 | E-GEOD-54108 | biostudies-arrayexpress

A cDNA microarray analysis was performed on shRNA KDs of EZH2, SUZ12, BMI1, or CBX8 HepG2 cells.

2014-01-16 | GSE54108 | GEO

MYC-HCC treated with immunotherapy

Project description:MYC-HCC treated with immunotherapy

| PRJNA888064 | ENA